Comparing two drug combinations for advanced hormone-positive breast cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial compares two standard hormone therapy pill combinations for advanced breast cancer. One adds a higher dose of palbociclib plus hydroxychloroquine, while the other uses the standard palbociclib dose, to see if the higher dose is more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- Your breast cancer is hormone receptor-positive and HER2-negative, and it has spread or returned after initial treatment.
- You have not had any prior treatment for the advanced disease.
- You are able to care for yourself (ECOG score 0-1) and have adequate blood, liver, and kidney function.
- You do not have serious heart, digestive, or eye conditions that could interfere with the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study uses a specialized laser test on a blood sample to predict how well palbociclib plus letrozole or anastrozole will work. It’s for certain postmenopausal women with HER2-negative, hormone-receptor positive, advanced (stage IIIb/IV) breast cancer.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This study looks at how well a combination of two medicines (a CDK4/6 inhibitor and an aromatase inhibitor) works for people with a certain type of advanced breast cancer. It aims to gather real-world information to better understand treatment patterns and outcomes.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This trial compares two treatment options for advanced breast cancer that has low hormone receptor levels and is HER2-negative. It tests whether a combination of chemotherapy followed by maintenance therapy works better than a CDK4/6 inhibitor combined with hormone therapy. This is for people who have not had chemotherapy for their advanced disease.
This Phase 2 study tests how well a treatment plan using palbociclib followed by talazoparib (and possibly atezolizumab) works in certain people with advanced ER-positive breast cancer. It may help by targeting cancer biology linked to BRCA/HRD changes and by strengthening how the cancer is controlled.
Hear when a new Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.